<DOC>
	<DOCNO>NCT01005771</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , parallel-group , dose-finding study .</brief_summary>
	<brief_title>Study Assess Efficacy Safety GF-001001-00 Cream Secondarily-Infected Traumatic Lesions</brief_title>
	<detailed_description>200 eligible patient include double-blind phase ( 50 group , randomise 1:1:1:1 GF-001001-00 concentration 0.25 % , 1 % 2 % placebo ) . Randomised patient apply study medication follow depend assign treatment group . - GF-001001-00 2 % , 2 time daily , 7 day - GF-001001-00 1 % , 2 time daily , 7 day - GF-001001-00 0.25 % , 2 time daily , 7 day - Placebo , 2 time daily , 7 day The first application do randomisation Visit 1 guidance investigator . Patients return control visit : Visit 2 ( Day 5 ) Visit 3 ( Day 7 ) , randomisation . Patients return Final Visit ( Visit 4 , Day 14 initiation treatment ) . Primary objective : To determine effective dose GF-001001-00 cream treatment adult patient secondarily infect traumatic lesion . Primary efficacy endpoint : Clinical response ( success failure ) Final Visit ( Day 14 ) ITTC population .</detailed_description>
	<criteria>Males female â‰¥ 18 year age . Presence small laceration , suture wound , abrasion burn , secondary bacterial infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Secondarily infect traumatic lesion</keyword>
</DOC>